Abstract:Our paper, “Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism” (Addiction. 2020 Feb;115(2):239-246) [1] generated interest from readers [2,3] on how to interpret the findings, and the role of cognitive and motivational processes, as opposed to conditioning, that may underlie patients’ differing behavioral responses to blocked opioid use. We appreciate Dr. Kunoe’s close reading of our paper. His commentary [2] highlights the potential complexity underlying antagonist treatment for opioid use disorder (OUD) and important directions for future research. Our paper emphasized the mechanism of extinction [1] because of the impressive phenomenon that naltrexone, at adequate blood levels, fully blocks the subjective and reinforcing effects of opioids, at least for most patients [4] and aids in mitigating most opioid use. We also discussed cognition and expectancy as mechanisms— the patient experiences the blockade and knows that the effects of future doses of opioids will be blocked, or has been instructed that there will be blockade and thus expects it. Dr. Kunoe argues that cognition and motivation are the more useful models [2], and he has a point. Patients in our study undoubtedly varied in their motivation entering the trial, wavered during the trial, and likely expected blockade. We were unable to

Reply to Kunoe (2020) and Ghosh and Singh (2020) regarding: Nunes et al., Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. Addiction. 2020 Feb;115(2):239-246.